<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04342923</url>
  </required_header>
  <id_info>
    <org_study_id>PI 20-1679</org_study_id>
    <nct_id>NCT04342923</nct_id>
  </id_info>
  <brief_title>Early POstoperative BIomarkers in PancreatoDuodenectomy: a Spanish Nationwide Study</brief_title>
  <acronym>EPOBIPD</acronym>
  <official_title>Early POstoperative BIomarkers in PancreatoDuodenectomy as Predictors of Complications: a Spanish Nationwide Multicentric Validation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clínico Universitario de Valladolid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clínico Universitario de Valladolid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AIMS: To recruit a large nationwide Spanish series in order to register PF rate and other&#xD;
      common morbidity after PD, and to perform external validation of the aforementioned score, as&#xD;
      well as to analyze other postoperative blood parameters and biomarkers associated with&#xD;
      complications.&#xD;
&#xD;
      METHODS: Observational prospective and multicentric cohort study to perform external&#xD;
      validation of the above-mentioned score. All Spanish centers/units performing PD are invited&#xD;
      to include participants. Patients will be consecutively recruited during an 8-10 months&#xD;
      period, regardless of their annual volume of pancreatic surgery.&#xD;
&#xD;
      Study variables will be hemogram parameters on POD1 and POD2 (specifically lymphocytes),&#xD;
      other parameters and biomarkers (RCP, lactate, procalcitonin, amylase, lipase, albumin) and&#xD;
      the common variables concerning PD studies.&#xD;
&#xD;
      LIMITATIONS: Heterogeneity in perioperative management and in blood analysis measuring since&#xD;
      this is a multicenter study. Possibility of underestimating the PF rate in patients without&#xD;
      surgical drainage. Finally, the cases of mini-invasive approach or pancreatogastrostomy will&#xD;
      receive a specific subgroup analysis since the score was designed on a series of open PD and&#xD;
      pancreatojejunostomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND: Complications after pancreatoduodenectomy (PD) are common and pancreatic fistula&#xD;
      (PF) is among the most relevant ones. There are few studies analyzing blood parameters&#xD;
      determined in the early postoperative period which behave as morbidity predictors. One of&#xD;
      them defined a new and simple prognostic score based on lymphocytes count on the first&#xD;
      postoperative day (POD1) and reactive C protein (RCP) on POD2. The internal validation&#xD;
      statistics of the score designed in the mentioned work were satisfactory. However, that score&#xD;
      was described in a short unicentric series&#xD;
&#xD;
      EXPECTED SAMPLE SIZE: Expected sample size is approximately 500 patients, which will show&#xD;
      error &lt;7.2% (with 95% confidence) for estimation score´s sensitivity and specificity. We have&#xD;
      assumed that the PF rate is around 30%.&#xD;
&#xD;
      QUALITY CONTROL: The STrengthening the Reporting of OBservational studies in Epidemiology&#xD;
      (STROBE) guidelines for the correct communication and publication of observational studies&#xD;
      will be followed. Likewise, in order to validate the aforementioned score, Transparent&#xD;
      Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD)&#xD;
      will be added. The only expected failure of the 20 items that compose the TRIPOD is 6b&#xD;
      (&quot;notify the actions for masking the analysis&quot;), since it is not applicable in our case.&#xD;
&#xD;
      The inclusion of patients operated on with a mini-invasive approach (laparoscopic or robotic)&#xD;
      or the use of other anastomoses (pancreatogastrostomy) or reconstruction (Roux-en-Y) differs&#xD;
      from the technique used in the series with which the score was originally defined (allof&#xD;
      them, open PD with pancreato-jejunostomy and, mostly part, tutored ducto-mucosal suture and&#xD;
      Child's single loop reconstruction). If discrepancies are detected, the corresponding&#xD;
      subgroup analysis will be performed. Cases of conversion from a mini-invasive to open&#xD;
      approach will be counted as such (intention-to-treat analysis).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pancreatic fistula rate</measure>
    <time_frame>90 days since PD</time_frame>
    <description>Pancreatic fistula including biochemical, grade B and grade C according to ISGPS updated criteria 2016</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinically relevant pancreatic fistula</measure>
    <time_frame>90 days since PD</time_frame>
    <description>Pancreatic fistula including grade B and grade C according to ISGPS updated criteria 2016</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall complications</measure>
    <time_frame>90 days since PD</time_frame>
    <description>Presence of any kind of complications including grades I to V according to Dindo-Clavien Classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe morbidity</measure>
    <time_frame>90 days since PD</time_frame>
    <description>Presence of any kind of complications including grades IIIa to V according to Dindo-Clavien Classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days since PD</time_frame>
    <description>Patient´s death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comprehensive Complication Index</measure>
    <time_frame>90 days since PD</time_frame>
    <description>Postoperative morbidity index (0-100 points) obteined by using formula described by Slankamenac et al Ann Surg 2013</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">525</enrollment>
  <condition>Pancreaticoduodenectomy</condition>
  <arm_group>
    <arm_group_label>Complete cohort</arm_group_label>
    <description>All patients undergoing PD during study period in all participating center/units in Spain.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>Blood analysis</description>
    <arm_group_label>Complete cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing PD in Spain&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  benign or malignant condition requiring surgical treatment by PD.&#xD;
&#xD;
          -  Signing the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intra-operative findings of unresectability (pancreatic resection not be completed or&#xD;
             palliative procedure performed)&#xD;
&#xD;
          -  Other types of pancreatic resection (enucleations, distal and total pancreatectomies),&#xD;
             as well as multivisceral resective procedures.&#xD;
&#xD;
          -  Intraoperative radiotherapy&#xD;
&#xD;
          -  ASA IV patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Rodriguez-Lopez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinico Universitario de Valladolid (España)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mario Rodriguez-Lopez, MD, PhD</last_name>
    <phone>983420000</phone>
    <phone_ext>86266</phone_ext>
    <email>mariorodriguezlopez@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carlos A Jezieniecki-Fernandez, MD</last_name>
    <phone>983420000</phone>
    <phone_ext>86266</phone_ext>
    <email>carlos.jezieniecki@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clinico Universitario</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Rodriguez-Lopez, MD PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Rodriguez-Lopez M, Tejero-Pintor FJ, Bailon-Cuadrado M, Barrera-Rebollo A, Perez-Saborido B, Pacheco-Sanchez D. Impaired immune reaction and increased lactate and C-reactive protein for early prediction of severe morbidity and pancreatic fistula after pancreatoduodenectomy. Hepatobiliary Pancreat Dis Int. 2020 Feb;19(1):58-67. doi: 10.1016/j.hbpd.2019.05.003. Epub 2019 May 20.</citation>
    <PMID>31153788</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 9, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clínico Universitario de Valladolid</investigator_affiliation>
    <investigator_full_name>Mario Rodriguez-Lopez</investigator_full_name>
    <investigator_title>General and Digestive Surgeon, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>PANCREATICODUODENECTOMY</keyword>
  <keyword>COMPLICATIONS</keyword>
  <keyword>PANCREATIC FISTULA</keyword>
  <keyword>SCORE</keyword>
  <keyword>BIOMARKERS</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

